PolyTherics has developed three proprietary technologies for attaching polyethylene glycol (PEG) to therapeutic peptides and proteins to slow drug elimination and extend duration of action. Its PEGylation approaches enable site-specific conjugation without reengineering protein sequences and have been applied to a range of existing proteins, peptides and novel protein scaffolds. The technology aims to allow less frequent dosing, potentially decreasing side effects and improving patient compliance. Led by CEO John Burt, the company positions its platform for broader application across protein and peptide therapeutics. PolyTherics intends to use the new funding to apply its technologies to an expanding range of proteins and peptides and to pursue new applications, including providing a more stable linker for antibody and protein drug conjugates. The company has completed multiple financings, demonstrating continued investor support for its platform. PolyTherics is a London, UK–based developer of a suite of technologies aimed at improving the properties of biologics for therapeutic use. Its proprietary PEGylation platforms, HiPEG™ and CyPEG, are being developed for novel peptides and proteins as potential “biobetter” products. The company completed a £3.0m funding round to advance those platforms. The financing follows a prior £2.3m round in June 2007 backed by the same investor syndicate. As part of the transaction, Imperial Innovations appointed Robert Bahns to PolyTherics' board. Two non-executive directors, Till Medinger and Stephane Mery, resigned in conjunction with the financing.

Total raised

$8M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2011